BACKGROUND: Malignant ascites is a common complication seen in association with various types of neoplastic processes. Due to high recurrence rates, patients may require multiple paracenteses, which have associated complications such as increased risk of bleeding, infection, pain, and volume and electrolyte depletion. OBJECTIVE: This study evaluated the management of malignant ascites by placement of the PleurX® tunneled catheter system at a single center. METHODS: This was a retrospective study of 38 patients who underwent PleurX catheter placement for refractory malignant ascites between February 2006 and March 2012 at our institution. Pretreatment characteristics and outcome measures were reported using descriptive statistics. RESULTS: The population included 21 males and 17 females with a mean age of 60.6 years (range, 36-79 years) diagnosed with metastatic disease from a variety of primary malignancies, the most common of which was pancreatic cancer (10 patients). In 84% of patients (32/38) who were not lost to follow-up, mean survival time was 40.7 days (range 4-434 days). Technical success rate of catheter placement was 100%. CONCLUSIONS: The PleurX catheter can be used to manage malignant ascites in severely ill patients with metastatic cancer, with a high rate of procedural success and a low incidence of potentially serious adverse events, infections, or catheter-related complications.
BACKGROUND:Malignant ascites is a common complication seen in association with various types of neoplastic processes. Due to high recurrence rates, patients may require multiple paracenteses, which have associated complications such as increased risk of bleeding, infection, pain, and volume and electrolyte depletion. OBJECTIVE: This study evaluated the management of malignant ascites by placement of the PleurX® tunneled catheter system at a single center. METHODS: This was a retrospective study of 38 patients who underwent PleurX catheter placement for refractory malignant ascites between February 2006 and March 2012 at our institution. Pretreatment characteristics and outcome measures were reported using descriptive statistics. RESULTS: The population included 21 males and 17 females with a mean age of 60.6 years (range, 36-79 years) diagnosed with metastatic disease from a variety of primary malignancies, the most common of which was pancreatic cancer (10 patients). In 84% of patients (32/38) who were not lost to follow-up, mean survival time was 40.7 days (range 4-434 days). Technical success rate of catheter placement was 100%. CONCLUSIONS: The PleurX catheter can be used to manage malignant ascites in severely ill patients with metastatic cancer, with a high rate of procedural success and a low incidence of potentially serious adverse events, infections, or catheter-related complications.
Authors: Angi Courtney; Albert A Nemcek; Stefanie Rosenberg; Sean Tutton; Michael Darcy; Greg Gordon Journal: J Vasc Interv Radiol Date: 2008-10-31 Impact factor: 3.464
Authors: Jong Yun Won; Sun Young Choi; Heung-Kyu Ko; Seung Hyung Kim; Kwang-Hun Lee; Jong Tae Lee; Do Yun Lee Journal: J Vasc Interv Radiol Date: 2008-10-23 Impact factor: 3.464
Authors: Piera Cote Robson; Mithat Gonen; Ai Ni; Lynn Brody; Karen T Brown; George Getrajdman; Bridgette Thom; Nancy Kline; Anne Covey Journal: Palliat Support Care Date: 2019-12
Authors: Christina Fotopoulou; Thomas Berg; Annekristin Hausen; René Hennig; Rajiv Jalan; Massimo Malagó; Jeroen Capel; Andrea De Gottardi; Guido Stirnimann Journal: BMC Palliat Care Date: 2019-12-05 Impact factor: 3.234